Form 4: Kalaris Therapeutics CEO Andrew Oxtoby Reports Stock Option Grant

Andrew Oxtoby, CEO of Kalaris Therapeutics, reports the acquisition of stock options.

Summary

• Andrew Oxtoby, the President and CEO of Kalaris Therapeutics, Inc. [KLRS], filed a Form 4 on April 11, 2025.
• The filing reports a transaction that occurred on April 10, 2025, where Oxtoby acquired a stock option to purchase 287,000 shares of Kalaris Therapeutics common stock at an exercise price of $7.31.
• The options vest over four years, starting with 25% vesting on March 18, 2026, and the remainder vesting in equal monthly installments thereafter, contingent upon continuous service.
• The expiration date for the options is April 9, 2035.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of a stock option grant, which is generally viewed as a positive incentive for management but doesn't necessarily indicate strong positive or negative sentiment about the company's prospects.

Positives

• The grant of stock options to the CEO aligns his interests with those of the shareholders, incentivizing him to increase the company's value.
• The vesting schedule encourages long-term commitment from the CEO.

Future Outlook

The document does not contain specific forward-looking statements about the company's future performance, but the stock option grant suggests an expectation of continued service and potential value creation by the CEO.

Management Comments

• Andrew Oxtoby, President and Chief Executive Officer, signed the Form 4.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Vesting schedules of four years with a one-year cliff (25% vesting after one year) are typical.
• The size of the grant (287,000 shares) would need to be compared to grants given to CEOs of similarly sized biotech companies to assess its relative magnitude.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, aligning management's interests with their own.
• Employees may see the grant as a sign of confidence in the company's future.

Key Dates

Keywords

Form 4, stock options, Kalaris Therapeutics, Andrew Oxtoby, beneficial ownership, KLRS